HC Wainwright Reaffirms “Buy” Rating for Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $8.00 target price on the stock.

Other research analysts also recently issued reports about the company. LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Brookline Cap M upgraded Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Roth Mkm began coverage on shares of Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 price target on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Immunic in a research report on Wednesday, January 7th. Four research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Immunic presently has a consensus rating of “Buy” and a consensus target price of $7.40.

Immunic Stock Performance

NASDAQ IMUX opened at $0.62 on Monday. Immunic has a one year low of $0.51 and a one year high of $1.39. The company has a market capitalization of $74.58 million, a price-to-earnings ratio of -0.75 and a beta of 1.58. The company’s 50-day simple moving average is $0.63 and its two-hundred day simple moving average is $0.77.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. Equities analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Immunic

Several large investors have recently bought and sold shares of IMUX. Qube Research & Technologies Ltd acquired a new position in Immunic during the 3rd quarter valued at approximately $29,000. Two Sigma Investments LP purchased a new stake in shares of Immunic during the third quarter valued at $52,000. HB Wealth Management LLC acquired a new position in shares of Immunic in the 3rd quarter valued at $81,000. Virtu Financial LLC purchased a new position in Immunic in the 3rd quarter worth $99,000. Finally, GSA Capital Partners LLP acquired a new stake in Immunic during the 3rd quarter worth about $170,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.